Brokerage firm JP Morgan Upgrades its rating on Mead Johnson Nutrition CO(NYSE:MJN). The shares have been rated Overweight. Previously, the analysts had a Neutral rating on the shares. The rating by JP Morgan was issued on Jul 26, 2016.
In a different note, On Jul 25, 2016, Citigroup said it Maintains its rating on Mead Johnson Nutrition CO. In the research note, the firm Raises the price-target to $100.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 13, 2016, Bank of America said it Upgrades its rating on Mead Johnson Nutrition CO. The shares have been rated ‘Neutral’ by the firm.
Mead Johnson Nutrition CO (MJN) shares turned negative on Fridays trading session with the shares closing down -0.69 points or -0.77% at a volume of 20,67,616. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $90.515. The peak price level was also seen at $90.515 while the days lowest was $88.86. Finally the shares closed at $89.2. The 52-week high of the shares is $94.4 while the 52-week low is $65.53. According to the latest information available, the market cap of the company is $16,650 M.
Mead Johnson Nutrition CO(MJN) last announced its earnings results on Apr 28, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $962.10M. Analysts had an estimated revenue of $955.13M. Earnings per share were $0.87. Analysts had estimated an EPS of $0.85.
Several Insider Transactions has been reported to the SEC. On May 3, 2016, Christoper Richard Stratton (SVP and President, Asia) sold 33,730 shares at $86.68 per share price.Also, On Dec 14, 2015, Michel Martinus Gerardus Cup (CFO) purchased 4,000 shares at $76.50 per share price.On Nov 25, 2015, Robert S Singer (director) sold 4,000 shares at $81.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Mead Johnson Nutrition Company (Mead Johnson) is a global pediatric nutrition company. The Company manufactures distributes and sells infant formulas children’s nutrition and other nutritional products. Its product portfolio includes routine and specialty infant formulas childrens milks and milk modifiers dietary supplements for pregnant and breastfeeding mothers pediatric vitamins and products for pediatric metabolic disorders. The Company operates through three segments: Asia Latin America and North America/Europe. The Company’s Enfa family of brands including Enfamil infant formula is a brand franchise in pediatric nutrition. Its product portfolio addresses a range of nutritional needs for infants children and expectant and nursing mothers. The Company markets its portfolio of more than 70 products to mothers healthcare professionals and retailers in more than 50 countries in Asia North America Latin America and Europe.